Status:
UNKNOWN
Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo
Conditions:
Metastatic Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate, in terms of overall survival, the benefit of monoclonal antibodies in the start time of the diagnosis of advanced disease or administer a deferred basis after...
Eligibility Criteria
Inclusion
- Patients diagnosed with metastatic colorectal cancer with biopsy positive for adenocarcinoma.
- ECOG PS0-2.
- Who have not received prior chemotherapy treatment for metastatic disease.
- Measurable or evaluable disease.
- No previous surgery for metastatic disease. Surgery for metastasis allowed after inclusion in the study aftercare at the discretion of investigadors.
- Chemotherapy treatment with doublets (CAPOX, FOLFOX, FOLFIRI)
Exclusion
- Patients older than 70 years with frailty criteria.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
1104 Patients enrolled
Trial Details
Trial ID
NCT02254941
Start Date
August 1 2014
End Date
December 1 2022
Last Update
March 16 2022
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Virgen de los Lirios
Alcoy, Alicante, Spain
2
Hospital General Universitario de Elche
Elche, Alicante, Spain, 03203
3
Hospital Universitario del Vinalopó
Elche, Alicante, Spain
4
Hospital General Universitario de Elda
Elda, Alicante, Spain